Background: On October 24th, 2018, Roche, the maker of oseltamivir, announced that the US Food and Drug Administration (FDA) approved Xofluza (baloxavir marboxil) for the treatment of acute, uncomplicated influenza in people 12 years of age and older. Historically, there ...
Background: Cricoid pressure is dead, right? Many have made this claim including a brilliant argument against its use by John Hinds here. Despite the many eulogies, we continue to hear about cricoid pressure so it makes sense that we dive ...
In October 2016, I was exposed to the vast world of Free Open Access Medical Education and MedTwitter. I was astounded and inspired by the different educators who were trying to make learning easier. The Knowledge Translation (KT) gap was ...
Background: In the United States 424,000 out of hospital cardiac arrests occur per year with a 10.4% overall survival rate.1 Refractory Ventricular Fibrillation (RVF) is a complication of cardiac arrest and has varying definitions in the literature but is commonly defined ...
Background: Care of trauma patients with severe bleeding has advanced in recent years with a focus on damage control resuscitation which includes permissive hypotension, hemostatic resuscitation (blood component resuscitation), and hemorrhage control. Minimizing crystalloids in favor of blood component-based resuscitation in ...
Background: Keeping up to date with the current literature is no small task. You may say it is like drinking from a firehose when you’re thirsty; it can be painful and, at the end, does it really quench our thirst? The ...
Background:In the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial , there was no difference in MI and death rates between patients with stable coronary artery disease who underwent PCI and controls. In stable angina, the primary goal of ...
Background: Establishing IV access has become the norm for patients presenting to the ED. However with increasing patient volumes, difficulty and delays in acquiring IV access, it seems that anything that could expedite care, reduce pain and suffering, and improve patient ...
Background: Oseltamivir (Tamiflu), a neuraminidase inhibitor, was approved by the FDA in 1999. The majority of the evidence supporting the use of the medication came from trials funded by Roche, the maker of the drug. Safety issues with the drug ...
Background: Headache is a common presentation to the emergency department (ED) accounting for 2% of all visits . Of the patients that present with headache,1 – 3% will be due to a subarachnoid hemorrhage (SAH) . SAH is a true diagnostic ...
1 email per week. No spam.
Sponsored
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.